Combination erythropoietin-hydroxyurea therapy in sickle cell disease: Experience from the National Institutes of Health and a literature review

Jane A. Little, Vicki R. McGowan, Gregory J. Kato, Kristine S. Partovi, Jordan J. Feld, Irina Maric, Sabrina Martyr, James G. Taylor VI, Roberto F. Machado, Theo Heller, Oswaldo Castro, Mark T. Gladwin

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

Erythropoietin is being used more widely in the management of sickle cell disease (SCD, inclusive of homozygous sickle beta, SS, and compound heterozygous sickle beta thalassemia, Sβ° thal), often in conjunction with hydroxyurea (HU). Herein, we summarize the published experience with erythropoietin use in SCD, in 39 patients (SS, n=30; Sβ° thal, n=9) who were treated between 1990 and 1996; and in 13 patients with sickle syndromes (SS, n=12, compound heterozygous SC disease, n=1) who were treated with erythropoietin or darbepoietin at the National Institutes of Health (NIH) since 2002. The dose range of erythropoietin for SCD in the published series, at a median of >200 U/Kg/dose, is higher than that used in end-stage renal disease. The median duration of erythropoietin therapy was ≥3 months, with minimal reported side-effects. At the NIH, the median age of sickle syndrome patients who received erythropoietin or darbepoietin (both referred to as EPO in the NIH series) was 51 (24 to 70) years; 12/13 patients had sickle-associated pulmonary hypertension. Eleven out of the 13 patients were treated with both HU and EPO for > 4 months (median of 11 months on EPO) without complication. Of the 13 patients, five (all SS) with pulmonary hypertension were given EPO for reticulocytopenia (<100,000/μL) on HU; 5/13 patients (all SS), with pulmonary hypertension, were given EPO and HU concurrently, in the light of an estimated glomerular filtration rate of <80 mL/minute. Three of the 13 patients (2 SS, 1 SC) were treated with EPO for miscellaneous reasons. Hematologic responses, detailed herein, suggest that EPO therapy may allow more aggressive HU dosing in high-risk SCD patients and in the setting of mild renal insufficiency, common to the aging sickle cell population. Furthermore EPO appears to be safe in SCD, particularly when used in conjunction with HU. We outline our current therapeutic strategy for EPO use in SCD.

Original languageEnglish (US)
Pages (from-to)1076-1083
Number of pages8
JournalHaematologica
Volume91
Issue number8
StatePublished - Aug 1 2006
Externally publishedYes

Keywords

  • Erythropoietin
  • Hydroxyurea
  • Pulmonary hypertension
  • Sickle cell disease

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Combination erythropoietin-hydroxyurea therapy in sickle cell disease: Experience from the National Institutes of Health and a literature review'. Together they form a unique fingerprint.

  • Cite this

    Little, J. A., McGowan, V. R., Kato, G. J., Partovi, K. S., Feld, J. J., Maric, I., Martyr, S., Taylor VI, J. G., Machado, R. F., Heller, T., Castro, O., & Gladwin, M. T. (2006). Combination erythropoietin-hydroxyurea therapy in sickle cell disease: Experience from the National Institutes of Health and a literature review. Haematologica, 91(8), 1076-1083.